Skip to main content

Summary

for people ages 18–65 (full criteria)
at Fresno, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.

Official Title

Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study

Keywords

Multiple Sclerosis progressive multiple sclerosis MS EDSS TW25 Sclerosis

Eligibility

You can join if…

Open to people ages 18–65

  • Patient aged 18-65 years old
  • Signed and dated written informed consent form in accordance with local regulations:having freely given their written informed consent to participate in the study
  • Diagnosis of primary or secondary progressive MS fulfilling revised McDonald criteria(2010) and Lublin criteria (2014)
  • Documented evidence of clinical disability progression within the 2 years prior to inclusion, i.e. a) progression of EDSS during the past two years of at least 1 point sustained for at least 6 months if inclusion EDSS is from 3.5 to 5.5 or at least 0.5 point increase sustained for at least 6 months if inclusion EDSS is from 6 to 6.5 or b) increase of TW25 by at least 20% in the last two years sustained for at least 6 months or c) other well-documented objective worsening validated by the Adjudication Committee
  • EDSS at inclusion from 3.5 to 6.5
  • TW25 < 40 seconds
  • Kurtzke pyramidal functional subscore ≥2 defined as "minimal disability: patient complains of motor-fatigability or reduced performance in strenuous motor tasks (motor performance grade 1) and/or BMRC grade 4 in one or two muscle groups"

You CAN'T join if...

  • Clinical evidence of a relapse in 24 months prior to inclusion
  • Treatment with any product containing biotin as single ingredient within six months prior to inclusion (multivitamin supplementation authorized if biotin < 1mg per day)
  • Concomitant treatment with fampridine at inclusion or in the 30 days prior to inclusion
  • New immunosuppressive/immunomodulatory drug initiated less than 90 days prior to inclusion
  • Treatment with botulinium toxin (except for cosmetic purpose) initiated within 6 months prior to inclusion
  • In-patient rehabilitation program within the 3 months prior to inclusion
  • Pregnancy, breastfeeding or women with childbearing potential without acceptable form of contraception
  • Men unwilling to use an acceptable form of contraception
  • Any general chronic handicapping/incapacitating disease other than MS
  • Any serious disease necessitating biological follow-up with biological tests using biotinylated antibodies or substrates
  • Past history of rhabdomyolysis/metabolic myopathy
  • Known fatty acids beta oxidation defect
  • Known hypersensitivity or intolerance to biotin, analogues or excipients, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
  • Patients with hypersensitivity or any contra-indication to Gadolinium
  • Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or cancer
  • Laboratory tests out of normal ranges considered by the investigator as clinically significant with regards to the study continuation
  • Patients with history or presence of alcohol abuse or drug addiction
  • Untreated or uncontrolled psychiatric disorders, especially suicidal risk assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Participation in another research study involving an investigational product (IP) in the 90 days prior to inclusion, or planned use during the study duration
  • Patients likely to be non-compliant to the study procedures or for whom a long-term follow-up seems to be difficult to achieve
  • Relapse that occurs between inclusion and randomization visit

Locations

  • Neuro-Pain Medical Center not yet accepting patients
    Fresno, California, 93710, United States
  • UCSF Multiple Sclerosis Center accepting new patients
    San Francisco, California, 94117, United States
  • Sutter East Bay Medical Foundation accepting new patients
    Berkeley, California, 94705, United States
  • UC Davis Health System accepting new patients
    Sacramento, California, 95817-2307, United States
  • University of Southern California Keck School of Medicine accepting new patients
    Los Angeles, California, 90033, United States
  • MS Center of California accepting new patients
    Newport Beach, California, 92663, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MedDay Pharmaceuticals SA
Links
Sponsor
clinical trial dedicated website
ID
NCT02936037
Phase
Phase 3
Lead Scientist
Bruce Cree
Study Type
Interventional
Last Updated
October 6, 2017
I’m interested in this study!